Department of Neurological Surgery, Sonoda Daiichi Hospital, Tokyo, Japan.
Adv Exp Med Biol. 2024;1463:167-172. doi: 10.1007/978-3-031-67458-7_28.
Prevention of delayed cerebral infarction (DCI) due to cerebral vasospasm after subarachnoid haemorrhage (SAH) has been done with intravenous Rho kinase inhibitors (ROCKI), ozagrel sodium (TXA2I), selective ROCKI infusion (ROCKI i.a.), and cerebrospinal fluid (CSF) drainage. The endothelin receptor antagonist (ERA, clazosentan) became available in 2022 and is said to be highly recommended for DCI prevention, while fluid retention such as pleural effusion and pulmonary oedema accumulation is often experienced. We investigated the relationship between patient background, fluid retention, and ERA. Ten consecutive SAH patients treated with ERA from July to December 2022 were included. We examined the results of blood sampling on admission, echocardiography, chest computed tomography (CT), with postoperative DCI, and hydrocephalus requiring cerebrospinal fluid shunt (hydro), and symptomatic fluid retention requiring albumin and furosemide (third fluid space). Two males and eight females, mean age 63 years, mean preoperative World Federation Neurosurgical Surgeons (WFNS) grade 3.5, mean creatinine 0.94, mean brain natriuretic peptide (NT-proBNP). In 1883, two patients with Takotsubo cardiomyopathy and four patients with neurogenic pulmonary oedema are present. All patients underwent coil embolisation, and postoperative CSF drainage, ROCKI, TXA2I systemic administration, and ROCKI i.a. There were one DCI, three hydro, and five third fluid cases. Concerning the third fluid, the only significant difference was found in the age. An improvement in fluid retention after ERA discontinuation in old patients was shown. Our experience suggests that age may be the most influential factor. Based on these results, we have also found that by avoiding the use of ERA in patients older than 80 years, strictly limiting the infusion volume when using ERA, and actively using the drugs for heart failure early on, the frequency of suffering from third fluid space is reduced.
蛛网膜下腔出血(SAH)后脑血管痉挛导致的迟发性脑梗死(DCI)的预防措施包括静脉注射 Rho 激酶抑制剂(ROCKI)、奥扎格雷钠(TXA2I)、选择性 ROCKI 输注(ROCKI i.a.)和脑脊液(CSF)引流。内皮素受体拮抗剂(ERA,clazosentan)于 2022 年上市,据称对 DCI 的预防非常有效,但常伴有胸腔积液和肺水肿等体液潴留。我们调查了患者背景、体液潴留和 ERA 之间的关系。纳入了 2022 年 7 月至 12 月期间接受 ERA 治疗的 10 例连续 SAH 患者。我们检查了入院时的血液采样结果、超声心动图、胸部计算机断层扫描(CT)、术后 DCI、需要脑脊髓液分流(hydro)的脑积水和需要白蛋白和呋塞米(第三间隙)的症状性体液潴留。患者中 2 名男性,8 名女性,平均年龄 63 岁,平均术前世界神经外科学联合会(WFNS)分级 3.5 级,平均血肌酐 0.94,平均脑利钠肽(NT-proBNP)。在 1883 年,有 2 例 Takotsubo 心肌病和 4 例神经源性肺水肿患者。所有患者均接受了线圈栓塞术,术后 CSF 引流、ROCKI、TXA2I 全身给药和 ROCKI i.a.。有 1 例 DCI、3 例 hydro 和 5 例 third fluid 病例。关于 third fluid,只有年龄存在显著差异。在老年患者中,ERA 停药后体液潴留得到改善。我们的经验表明,年龄可能是最具影响力的因素。基于这些结果,我们还发现,通过避免在 80 岁以上的患者中使用 ERA,严格限制 ERA 的输注量,并尽早积极使用心力衰竭药物,可以降低 third fluid space 的发生频率。